Stock Track | Capricor Therapeutics Plummets 10.65% Intraday as Investors Take Profits After Positive DMD Trial Results

Stock Track

Dec 04

Capricor Therapeutics (CAPR) saw its shares plummet 10.65% during Thursday's intraday trading, extending a pre-market decline of 8.11%. The sharp drop follows a staggering 399% surge in the previous session after the company announced positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.

The decline is attributed to profit-taking by investors who capitalized on the stock's unprecedented gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally. Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also validated the results.

The volatility underscores the market's reaction to breakthrough clinical outcomes and subsequent investor behavior, with traders locking in profits after the historic surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156109403"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156109403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156109403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156109403","market":"nz","top_or_hot":-1,"title":"Stock Track | Capricor Therapeutics Plummets 10.65% Intraday as Investors Take Profits After Positive DMD Trial Results","media":"Stock Track","content":"<p>Capricor Therapeutics (CAPR) saw its shares plummet 10.65% during Thursday's intraday trading, extending a pre-market decline of 8.11%. The sharp drop follows a staggering 399% surge in the previous session after the company announced positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The decline is attributed to profit-taking by investors who capitalized on the stock's unprecedented gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally. Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also validated the results.</p><p>The volatility underscores the market's reaction to breakthrough clinical outcomes and subsequent investor behavior, with traders locking in profits after the historic surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Capricor Therapeutics Plummets 10.65% Intraday as Investors Take Profits After Positive DMD Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Capricor Therapeutics Plummets 10.65% Intraday as Investors Take Profits After Positive DMD Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-04 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Capricor Therapeutics (CAPR) saw its shares plummet 10.65% during Thursday's intraday trading, extending a pre-market decline of 8.11%. The sharp drop follows a staggering 399% surge in the previous session after the company announced positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The decline is attributed to profit-taking by investors who capitalized on the stock's unprecedented gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally. Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also validated the results.</p><p>The volatility underscores the market's reaction to breakthrough clinical outcomes and subsequent investor behavior, with traders locking in profits after the historic surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"","article_id":"1156109403","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156109403","pubTimestamp":1764859117,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Capricor Therapeutics (CAPR) saw its shares plummet 10.65% during Thursday's intraday trading, extending a pre-market decline of 8.11%. The sharp drop follows a staggering 399% surge in the previous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc"},"translate_title":"个股追踪|Capricor Therapeutics盘中暴跌10.65%DMD试验结果利好投资者获利了结","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"Capricor Therapeutics (CAPR) saw its shares plummet 10.65% during Thursday's intraday trading, extending a pre-market decline of 8.11%. The sharp drop follows a staggering 399% surge in the previous session after the company announced positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.The decline is attributed to profit-taking by investors who capitalized on the stock's unprecedented gains. The HOPE-3 study for Deramiocel met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients, which had initially fueled the rally. Nippon Shinyaku, which plans to market CAP-1002 in the U.S. if approved, also validated the results.The volatility underscores the market's reaction to breakthrough clinical outcomes and subsequent investor behavior, with traders locking in profits after the historic surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}